Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3051680 | 0.95 | MAP4K1 (0.35) | MAP4K1OPRL1STIM1ORAI1MAPT | |
| SCHEMBL13137219 | 0.87 | MAP4K1 (0.35) | MAP4K1OPRL1BACE1KCNH2 | |
| SCHEMBL3051522 | 0.84 | GRIN2B (0.32) | OPRL1MAPTOPRM1BACE1KCNH2 | |
| Hydrochloric Acid SCHEMBL3034905 | 0.83 | GRIN2B (0.31) | OPRL1OPRM1BACE1KCNH2 | |
| Hydrochloric Acid SCHEMBL3034658 | 0.83 | BACE1 (0.34) | MAP4K1STIM1ORAI1BACE1KCNH2 | |
| SCHEMBL13137235 | 0.82 | PDGFRB (0.36) | MAP4K1KCNH2 | |
| SCHEMBL13137251 | 0.82 | MAP4K1 (0.39) | MAP4K1 | |
| SCHEMBL13137246 | 0.82 | MAP4K1 (0.35) | MAP4K1OPRL1OPRM1 | |
| SCHEMBL13137230 | 0.82 | MAP4K1 (0.37) | MAP4K1STIM1ORAI1MAPTOPRM1 | |
| Hydrochloric Acid SCHEMBL3939331 | 0.81 | MAP4K1 (0.35) | MAP4K1OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | MAP4K1 1613/4885OPRL1 1/4885STIM1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.